Summary

The retrospective PROMETHEUS study demonstrated that patients with an acute coronary syndrome who underwent percutaneous coronary intervention were more likely to be treated by their physicians with prasugrel as opposed to clopidogrel if they were younger and had a lower risk factor burden. The adjusted rate of ischemic events and bleeding risk is similar with prasugrel and clopidogrel.